Most interestingly, the number of circulating Tαβ CD4+CD8lo cells, together with the IGHV mutational status, were independent surrogate biomarkers of the CLL clone kinetics and may be used to identify at diagnosis CLL A/0 patients at higher risk of disease progression. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.